The Filing Desk

argenx

ARGX · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

ARGX · Last close · November 19, 2026
$942.04

argenx's revenue rose 88.6% to $4.2 billion in fiscal 2025. Its operating margin was 24.8%, up from −1.0% a year earlier. Free cash flow was $679 million. The diluted share count rose 1.3%.

ARGENX SE Latest fiscal year ended December 31, 2025 20-F filed March 19, 2026 · 0001697862-26-000032 Updated
Revenue
$4.2B
88.6%
Operating margin
24.8%
25.8 pts
Net income
$1.3B
55.1%
Free cash flow
$679M
 
Return on equity
20.1%
2.8 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.

About these figures. argenx is a foreign company: it files an annual report on Form 20-F, prepared under international accounting standards (IFRS), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model.

What argenx does

argenx is a biotechnology company, based in the Netherlands with research in Belgium, that makes antibody medicines for autoimmune diseases, in which the body's immune system attacks its own tissue. Its one approved medicine, VYVGART, treats generalized myasthenia gravis (gMG), a disease that causes muscle weakness, and chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder, plus immune thrombocytopenia (ITP), a blood disorder, in Japan. It comes as a drip into a vein or as an injection under the skin, including a prefilled syringe, and is approved in more than 30 countries.

Nearly all of its money comes from selling VYVGART through its own sales teams in the U.S., Europe, Japan and Canada, and through a partner, Zai Lab, in Greater China. In 2025 it reported product net sales of $4.2 billion, and VYVGART passed $1 billion in sales in a single quarter for the first time. The company says VYVGART reached more than 19,000 patients. It names AstraZeneca, AbbVie, Amgen, Johnson & Johnson and Novartis among its competitors in autoimmune disease.

argenx is testing VYVGART's active ingredient, efgartigimod, in more than ten other diseases, along with newer drugs such as empasiprubart and adimanebart. Contract makers, chiefly Lonza and Fujifilm, produce its medicines. It had 1,863 full-time employees at the end of 2025.

Its biggest risks, as it describes them

  • Its sales rest almost entirely on one medicine, VYVGART, so anything that hurts it would hurt the whole business.
  • Competing drugs for the same diseases, including cheaper copies (biosimilars) once its exclusivity runs out.
  • Drug price controls, such as Medicare price negotiation in the U.S., that could cut what it can charge.
  • Clinical trials of new uses and new drugs may fail or be delayed, or regulators may not approve them.
  • Its reliance on a few contract manufacturers, chiefly Lonza and Fujifilm, to make its medicines.
From argenx's annual report on Form 20-F, filed March 19, 2026, in our words; the 20-F has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both. Where the filings' structured data doesn't give a year's net income, the column is blank.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2024 to 2025, earnings per share grew 53.1% a year and net income 55.1% a year, as new shares raised the share count by 1% and diluted each share's earnings.

Diluted earnings per share
US$ per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1,3358012,0491,5003,491
Debt incl. finance leases——7——
Net debt (negative means net cash)——−2,042——
Net debt to EBITDA—————
Debt to equity——0.0x——
Interest coverage−76.2x−184.4x−469.1x−8.8x258.2x
Current ratio8.4x9.2x9.8x7.3x5.2x
Quick ratio8.1x8.4x9.0x6.7x4.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−930.8%6,234.1%104.6%
Altman Z''12.6611.8010.58
Accruals ratio3.3%17.1%8.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassPass
Cash from operations is positiveFailFailPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomeFailFailFail
Debt fell relative to assets———
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin roseFailPassFail
Revenue rose relative to assetsPassPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put argenx side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
argenxFY2588.6%24.8%16.0%———
IncyteFY2521.2%29.5%26.4%79.4%−2.2x8Compare
BioMarin PharmaceuticalFY2512.9%12.7%22.5%5.8%−2.0x5Compare
United TherapeuticsFY2510.6%46.9%32.7%———Compare
BioNTechFY254.3%−49.0%9.8%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue——22784149710362,2524,248
Revenue growth———265.2%−47.4%1,105.7%−98.0%254.4%6,237.9%88.6%
Gross profit——————−19−822,0253,797
Research and development——842213715806638609831,364
Operating income——−82−199−478−349−720−425−221,054
Net income——−67−181−608−408−710−2958331,292
Diluted EPS (US$)———−4.69−13.40−7.99−13.05−5.1612.7819.57
Diluted shares (millions)19253339455154576566
Cash flow
Cash from operations———152−398−607−863−420−83685
Capital expenditure———2141126
Free cash flow———150−400−610−864−421−85679
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation———4497179157233235248
Balance sheet at fiscal year end
Cash and short-term investments——3223721,2171,3358012,0491,5003,491
Debt incl. finance leases———————7——
Total assets———1,6102,2792,8503,1344,5426,2028,683
Total liabilities———4306053163214457041,360
Shareholders' equity——6161,1801,6742,5342,8144,0985,4987,323
Margins and ratios
Gross margin——————−193.6%−231.6%89.9%89.4%
Operating margin——−381.0%−253.5%−1,158.1%−70.1%−7,184.7%−1,196.2%−1.0%24.8%
Net margin——−310.2%−230.9%−1,475.3%−82.1%−7,077.5%−830.4%37.0%30.4%
Free cash flow margin———191.0%−968.7%−122.8%−8,614.0%−1,185.2%−3.8%16.0%
Rule of 40 (growth + FCF margin)———456.2%−1,016.2%983.0%−8,712.0%−930.8%6,234.1%104.6%
Return on capital——————————
Return on equity————−42.6%−19.4%−26.5%−8.5%17.4%20.1%
Return on assets————−31.3%−15.9%−23.7%−7.7%15.5%17.4%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: argenx's Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with argenx.